The prognosis of elderly patients with AML after chemotherapy is poor. Allo-SCT is feasible in these patients, but data on prognostic factors and outcome are limited. We analyzed all 102 AML patients X55 years, who underwent allo-SCT at our institution from 1997 to 2008. OS and relapse-free survival (RFS) rates at 3 years are 39 and 37%, respectively. Multivariate analysis for OS revealed age X60 years and active (refractory or untreated before allo-SCT) or advanced (4CR1) disease as adverse prognostic factors. Patients transplanted in CR1 had a 3-year OS of 67 vs 27% for patients with active/advanced disease. Multivariate analysis for RFS revealed active/advanced disease as the only adverse factor. Patients transplanted in CR1 had a 3-year RFS of 70 vs 22% for patients with active/advanced disease. In all, 17% of patients suffered from acute GVHD Xgrade II. The risk for severe acute GVHD was increased after allo-SCT from mismatched donors. Nonrelapse mortality (NRM) was 23% at 1 year. The only risk factor for NRM was active/advanced disease. In conclusion, allo-SCT from related or unrelated donors yields very good results in elderly AML patients transplanted in CR1. Disease status at transplantation is the most important prognostic factor for transplantation success.
Introduction
The median age of patients with AML is above 60 years. 1 In general, the prognosis of AML worsens with increasing patient age. One reason is comorbidities in elderly patients. These often preclude patients from receiving intensive chemotherapy for remission induction. 2 In addition, disease characteristics of AML patients change with age. Elderly patients (above age 55) are significantly more likely to show adverse prognostic factors, such as aberrations of chromosomes 5 and 7, deletions of p53 or a complex karyotype. 3 Favorable cytogenetic aberrations (for example, CBF aberrations), however, occur with much lower frequency in these patients. Moreover, elderly patients show an inferior outcome even in the presence of favorable cytogenetics compared with younger patients. 4, 5 This leads to poor remission rates and overall and disease-free survival in elderly AML patients, even if intensive chemotherapy is administered. 3, 6 Because of the limitations of conventional chemotherapy, allo-SCT has been evaluated in elderly AML patients with good performance status. In several small series of patients, myeloablative allo-SCT was feasible. However, nonrelapse mortality (NRM) increased to over 40% after 3 years. 7, 8 With the development of conditioning regimens with reduced intensity (RIC), more elderly patients became eligible for an allo-SCT. 9, 10 In general, patients after RIC allo-SCT show reduced treatment-related mortality when compared with those with myeloablative allo-SCT. However, the relapse rate is increased, resulting in a similar OS of both transplantation strategies. Despite a broader use of allo-SCT in elderly AML patients in recent years, data on patient outcome and prognostic factors for transplantation success are still limited. 11 Therefore, we retrospectively analyzed all 102 AML patients X55 years who received an allo-SCT from related or unrelated donors at our institution since 1997. We show that allo-SCT yields excellent results in selected patients and we define risk factors for treatment failure.
Patients and methods

Patients
Between February 1997 and November 2008, 102 consecutive patients X55 years with AML underwent an allo-SCT from matched related or unrelated donors at our institution. Until December 2005, unrelated donors were routinely typed for HLA-A, -B, -DR and -DQ. Since 2006, donors were also typed for HLA-Cw. Acceptance of donors for transplantation followed published recommendations. 12 Patient characteristics are shown in Table 1 .
Conditioning regimens
The different conditioning regimens used are shown in Table 2 . In all, 14 patients received a myeloblative regimen, whereas 88 patients were treated with an RIC regimen.
Statistical analyses
The definition of CR and survival end points such as relapse-free survival (RFS) and OS followed the recommended consensus criteria. 13 NRM was defined as death from any cause without a previous relapse. The median follow-up time for survival was calculated according to the method of Korn. 14 OS end points, measured from the date of transplantation, were death (failure) and alive at last follow-up (censored). RFS end points, measured from the date of transplantation, were relapse (failure), death in CR (failure) and alive in CR at last follow-up (censored). A logistic regression model was used to analyze associations between patient characteristics and the development of acute or chronic GVHD. The Kaplan-Meier method was used to estimate the distribution of RFS, OS and NRM. Survival distributions were compared using the log-rank test. Variables with a P-value o0.1 were included in Cox models to identify independent prognostic variables. A conditional backwards-elimination procedure was used to exclude redundant or unnecessary variables. To provide quantitative information on the relevance of results, 95% confidence intervals (CIs) of hazard ratios (HR) were computed. For competing risk analysis, NRM was defined as death from any cause, with relapse as a competing risk, and incidence of relapse was defined as relapse with the competing risk NRM. The Aalen-Johannsen estimator was used for cumulative incidence functions of the competing risks relapse and NRM. For the competing risks NRM and relapse, the test of Gray was used for the comparisons of cumulative incidences. 15 Variables were included in proportional subdistribution hazard models for relapse and NRM according to Fine and Gray. Statistical analyses were performed using the software package of SPSS Version 15.0 (SPSS Inc., Chicago, IL, USA) and with the statistical computing environment R version 2.10.0 with software packages survival (version 2.35-7), cmprsk (version 2.2-1) and prodlim (version 1.1.3; http://www.Rproject.org). Analysis of data was approved by the ethics committee of Hannover Medical School.
Results
Engraftment
Of the 102 patients, 97 showed engraftment with a complete donor chimerism (defined as X95% donor in unselected 
Abbreviations: BFM ¼ BCNU/fludarabine/melphalan; ClAraC ¼ clofarabine/cytarabine followed by 4Gy TBI/cyclophosphamide; Cy ¼ cyclophosphamide; FLAMSA ¼ fludarabine/cytarabine/amsacrine followed by 4Gy TBI/cyclophosphamide; Flu ¼ fludarabine; MMF ¼ mycophenolate-mofetil.
PB cells assessed by DNA fingerprinting). Median time to reach full donor chimerism was 28 days (range 18-84 days). Five patients did not engraft. Of them, three died from infectious complications on or before day 30 after transplantation before engraftment. The other two had a primary graft failure and died on days 63 and 122, respectively, without recovery of neutrophils. There was no significant association between time to reach full donor chimerism and the different conditioning regimens.
Analysis for overall and relapse-free survival
The median follow-up time for survival is 33 months. Of the 102 patients, 56 died, resulting in a median survival of 18.7 months and a 3-year OS of 39% (95% CI 33-45%; Figure 1a ). Univariate and multivariate analysis for OS revealed two adverse factors: age X60 years (HR 1.9; 95% CI 1.1-3.2) and active/advanced disease (refractory or untreated before allo-SCT or 4CR1; HR 3.0; 95% CI 1. (Table 3) .
Of the 97 patients with engraftment, 35 relapsed and 20 died in CR, resulting in a median RFS of 14.3 months and a 3-year RFS of 37% (95% CI 32-42%; Figure 2a ). Median time to relapse was 20 months. In univariate analysis, age X60 years and active/advanced disease were adverse factors for RFS (Table 3) . However, in multivariate analysis for RFS, active/advanced disease (HR 3.8; 95% CI 1.8-8.3) was the only independent prognostic factor. The univariate Kaplan-Meier analysis is shown in Figure 2b . Patients transplanted in CR1 had a 3-year RFS of 70 vs 22% for patients with active/advanced disease. Again, RFS of patients transplanted in CR2 or CR3 did not differ significantly from patients transplanted with active disease (3-year RFS 21 vs 20%, P ¼ 0.49). The other factors analyzed also had no prognostic impact on RFS.
When relapse and NRM were analyzed as competing risks, active/advanced disease was still the only adverse risk factor for relapse (HR 2.4; 95% CI 1.0-6.0) and NRM (HR 4.5; 95% CI 1.1-19.6).
GVHD and NRM GVHD prophylaxis consisted of CsA plus mycophenolate mofetil in 61 patients and CsA plus MTX in 37 patients. In all, 86 patients received additional antithymocyte globuline (n ¼ 81) or Campath Ab (n ¼ 5) for in-vivo T-cell depletion. Four patients received T-cell-depleted grafts and no further pharmacological GVHD prophylaxis. Acute GVHD occurred in 42 (43%) patients with engraftment; in 17 (17%), GVHD was X1II. In a logistic regression model, none of the following characteristics proved to be an independent risk factor for the development of acute GVHD: age, active/advanced disease at transplantation, TBI-based conditioning, type of donor, comorbidity score and no. of CD34-positive cells infused. GVHD X1II, however, was increased after transplantation from a mismatched donor (OR 6.1; 95% CI 1.7-21.0). In contrast, there was a lower incidence of acute GVHD X1II in patients with in-vivo T-cell depletion by antithymocyte globulin or Campath Ab (OR 0.2; 95% CI 0.05-0.8). In univariate analysis, OS was not different between patients with or without acute GVHD. Chronic GVHD was diagnosed in 30 patients (31%); in 14 (14%), cGVHD was extensive. There was also a trend for a lower incidence of chronic GVHD in patients after in vivo T-cell depletion (OR 0.2; 95% CI 0.1-1.0; P ¼ 0.057). Other parameters had no influence on the development of limited or extensive chronic GVHD. In patients who survived X100 days, Of the 102 patients, 25 died without previous relapse. NRM was 15% on day 100 and 23% 1 year after transplantation (Figure 3a) . Causes of NRM were infections (n ¼ 18), complications from GVHD (n ¼ 4) or VOD (n ¼ 3). Multivariate analysis revealed active/advanced disease (HR 10.5; 95% CI 1.3-85.2) as the only independent prognostic factor for NRM (Figure 3b) . There was also a trend toward a higher NRM in patients with acute GVHD of any grade (HR 2.9; 95% CI 0.9-9.3; P ¼ 0.07).
Discussion
Several smaller series of patients and registry data have shown that myeloablative allo-SCT is feasible in elderly AML patients over the age of 55 years. 7, 8 In particular, the introduction of conditioning regimens with reduced intensity has increased the upper age limit for an Allo-SCT in elderly AML patients J Krauter et al allo-SCT. 9, 10, [16] [17] [18] However, information on prognostic factors for outcome after an allo-SCT in elderly patients with AML is still limited. We retrospectively analyzed all patients aged X55 years who received an allo-SCT for the treatment of AML at our institution from 1997 to 2008. As these patients were referred to our center especially for allo-SCT and actually received a transplant, patient selection is of course an issue. However, our analysis did not aim at the feasibility of an allo-SCT in elderly AML patients in general, but on the definition of risk factors for outcome in patients who are eligible for this therapeutic approach. As the analysis of our patients showed that most of them had significant comorbidities and that, in 95%, the hematopoietic cell transplantation-comorbidity index was intermediate or high, our patients certainly are representative of an elderly patient population. 19, 20 Overall survival and RFS rate of our 102 patients after 3 years was in the range reported by other investigators. 9, 21 More than 85% of the patients in our cohort received RIC allo-SCT. The indication for the use of RIC protocols is heavily influenced by age, performance status and comorbidities of the patients. Therefore, we did not perform a comparison between RIC and myeloablative transplants. Data from other investigators indicate that both treatment strategies result in a comparable OS. 9, 10, 16 Multivariate analysis for OS revealed two independent risk factors: age and, most important, disease status at transplantation. Patients who were transplanted in CR1 had a 3-year OS of 67% (vs 27% in patients transplanted in active/advanced disease). Prognosis was inferior not only in patients with active disease at the beginning of conditioning but also when allo-SCT was performed in CR2 or CR3. The association of disease status by marrow blasts and outcome has been reported earlier, the dismal prognosis after transplantation in CR2 and CR3, however, is compelling. 22 We conclude that if transplantation is an option for the elderly AML patient, it should be performed in CR1. Other factors had no impact on OS. This was also true for donor type (MRD vs MUD and fully matched vs one mismatch). This indicates that transplantation from unrelated donors is equally safe and effective as matched related donor transplantation. This is in line with data from Schetelig et al., who showed comparable outcomes in patients older than 50 years after transplantation from related or unrelated donors. 23 In contrast to other data, the comorbidity index did not have a major effect on outcome in our analysis. 24, 25 This finding implies that the discrimination power of the widely used comorbidity index might be limited in an elderly patient population.
OS after allo-SCT is mainly influenced by relapse and treatment-related mortality. Multivariate analysis for RFS also identified active/advanced disease as the main prognostic factor for outcome. Patients with active/advanced disease at the beginning of conditioning had a high relapse rate, although most of them were treated with protocols, which have shown promising activity in this situation. 26, 27 Treatment-related mortality in our cohort was 15% at day 100 and 23% after 1 year. This is lower compared with data from myeloablative allo-SCT in elderly patients and is consistent with previously reported data. We thus confirm that the use of RIC protocols is safe in elderly AML patients.
The incidence of acute GVHD as a major cause for NRM was low in our cohort, with only 17% of patients with acute GVHD X1II, even though 18 patients received grafts from mismatched donors. This might be explained by our frequent use of in vivo T-cell depletion (mainly by antithymocyte globulin), as such therapies have been shown to reduce the incidence of acute and chronic GVHD in younger patients. 28 However, although incidence and grade of acute GVHD was generally low, there was still a trend for increased NRM in patients with acute GVHD of any grade. This underlines the fact that strategies to reduce GVHD without compromising GVL activity are needed. Multivariate analysis for NRM again revealed active/advanced disease as the only independent risk factor. Taken together, our data confirm that allo-SCT can be performed with acceptable toxicity in elderly patients with AML. Disease status at the time of transplantation is the major prognostic factor for OS and RFS, as well as for NRM. In patients transplanted in CR1, excellent results can be achieved with survival rates 460% after 3 years. In these patients, who otherwise have a dismal prognosis, age alone should not be regarded as a contraindication against allo-SCT. Transplantation from related or unrelated donors should be considered and planned once CR has been achieved, regardless of the comorbidity index. It should not be postponed until Allo-SCT in elderly AML patients J Krauter et al relapse has occurred. In contrast, patients transplanted with active or advanced disease have an inferior outcome. In these patients, conditioning regimens with a higher antileukemic activity or experimental approaches should be evaluated.
